Treatment efficacy of anti-hypertensive drugs in monotherapy or combination

Abstract

Supplemental Digital Content is available in the text

Practical application of the ATOM study

“…The analysis was based on the results of the ATOM [4] study. Briefly, a Bayesian meta-regression of clinical trials whose main objective was to assess the efficacy of the drugs in the reduction of BP was conducted in this study.…”

“…We recently published the results of the ATOM [4] study, a meta-analysis of 208 clinical trials, with 94,305 patients included. [4] In this study, we found significant differences in the ability to reduce BP between the different drugs used in monotherapy and, more significantly, between the different pharmacological combinations. However, in this study, the drugs and combinations are expressed in mean doses resulting from the studies analyzed, making it difficult to apply them in practice.…”

Excessive dietary sodium intake and elevated blood pressure: a review of current prevention and management strategies and the emerging role of pharmaconutrigenetics

“…7 Most drugs achieve 10–15 mm Hg reduction in systolic blood pressure and 8–10 mm Hg reduction in diastolic blood pressure when used as monotherapy, although combination therapy has been found to be more effective in achieving target blood pressure control. 58 59 For first-line antihypertensive agents in the UK, NICE recommends an ACE inhibitor or ARB (angiotensin-receptor blockers) for individuals less than 55 years old and a CCB for blacks or for those 55 years old or older. 30 In the USA, a thiazide-type diuretic, ACE inhibitor, ARB or CCB are first-line antihypertensive agents for non-blacks; and a thiazide-type diuretic or CCB for blacks is recommended.…”

Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis

“…This risk may be ameliorated with antihypertensive treatment: a reduction in systolic BP of 10 mmHg translates into a 17% reduction in the incidence of coronary artery disease, a 27% reduction in stroke, a 28% reduction in heart failure, and a 13% reduction in all-cause mortality [ 5 ]. Pharmacological inhibition of the renin-angiotensin-aldosterone system has been robustly demonstrated to reduce blood pressure by numerous randomised clinical trials, meta-analyses and observational studies [ 6 , 7 ]. However, controversy persists over the comparative safety and efficacy of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs), particularly with regard to myocardial infarction (MI) [ 8 , 9 ].…”